Increasing consideration of the public health impact of cannabis legalization has led to a closer look at its impact on obesity. Cannabis is associated with weight loss and decreased opioid use, in spite of the munchies and the gateway theory of addiction. Weight loss and the consequent savings on health care for obesity-related complications need to be considered in economic and political analyses of cannabis legalization.
Last week we wrote about a study on CBD and cancer. The authors suggested that CBD was fighting cancer cells by blocking a receptor called GPR55. A study published this year in Biomedical Pharmacotherapies presented similar results with a very different interpretation.
Interactions between medications are very common, especially in elderly populations that medicate for pain, diabetes and high cholesterol. The geriatric population is also the fastest-growing group of medical cannabis users. Cannabis has demonstrated efficacy in treating pain, and some phytocannabinoids have been suggested for various metabolic conditions.
During the last week of June, more than 400 scientists from 25 countries met in Montreal for the 27th annual symposium of the International Cannabinoid Research Society (ICRS). Several presentations and posters showcased new findings about cannabidiol (CBD), the non-euphoric component of the cannabis plant that is transforming the medical marijuana landscape.
Food is medicine. This delicious pumpkin curry recipe by Nature Going Smart is full of ingredients with powerful healing properties.
There is growing interest among medical scientists in the gene-regulating properties of cannabidiol (CBD), the non-psychoactive plant cannabinoid. CBD reduces brain cancer and breast cancer cell proliferation and metastasis by inhibiting the expression of the ID-1 gene.